Pet Pharm Biotech Co., Ltd.

NT$50.10As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7762Healthcare
Country Taiwan
PE (Fwd) •••
TSR 2Y CAGR 28.59%
Div yield 0.49%
ROE 2.88%
Biological Products, Except Diagnostic Substances
Beta (5Y) 0.69
PE TTM 97.26
TSR TTM (33.63%)
Mkt cap NT$2.910B
ROIC 1.21%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$55
10.40%
13.93%
Hold 5|9|7|6|5
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.55
0.56
0.60
0.60
(1.03%)
6.97%
9.34%
9.29%
RevenueNT$M
385.4
375.0
373.8
380.3
6.65%
2.20%
(1.82%)
1.29%
Peers (US$87.64M)
Cap (US$)
PE
88.47M
132.0x
Capital
TTM
5Y
10Y
Leveragex
1.199
0.011
—
EBIT/Intx
7.685
2.208
1.663
Own earn%
(41.06)
(101.09)
(68.01)
Sh yield%
19.60
17.96
18.11
Owners
Insiders/Inst%
12.98
34.13
Short interest%
2.00
SBC / revenue%
3.71
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
7–15
$1 testx
−1.0
Incr. ROIC%
21